The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| AYTU | +42.68% | -98.7% | -58.05% | -100% |
| S&P | +12.66% | +85.37% | +13.13% | +227% |
Aytu Biopharma, Inc. is a specialty pharmaceutical company, which focuses on identifying, acquiring, and commercializing novel products. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.
No news articles found for Aytu BioPharma.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $13.89M | -16.2% |
| Gross Profit | $8.74M | -21.0% |
| Gross Margin | 62.95% | -3.8% |
| Market Cap | $18.63M | 32.8% |
| Market Cap / Employee | $0.22M | 0.0% |
| Employees | 83 | -18.6% |
| Net Income | $1.97M | 79.8% |
| EBITDA | -$0.70M | -154.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $32.63M | 62.3% |
| Accounts Receivable | $33.23M | 43.5% |
| Inventory | 10.1 | -14.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $11.47M | -0.9% |
| Short Term Debt | $16.93M | 156.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -11.05% | -5.7% |
| Return On Invested Capital | -59.60% | -5.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$0.62M | 53.4% |
| Operating Free Cash Flow | -$0.62M | 48.1% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.35 | 0.24 | 0.39 | 0.89 | 75.71% |
| Price to Sales | 0.21 | 0.14 | 0.22 | 0.57 | 102.90% |
| Price to Tangible Book Value | -0.49 | -0.39 | -0.97 | -0.73 | 28.00% |
| Price to Free Cash Flow TTM | 2.60 | 1.94 | 27.17 | - | |
| Enterprise Value to EBITDA | 11.62 | 3.80 | 3.51 | -46.20 | -404.12% |
| Free Cash Flow Yield | 38.4% | 51.6% | 3.7% | - | |
| Return on Equity | -18.1% | 3.3% | -60.8% | -50.2% | 134.80% |
| Total Debt | $17.14M | $22.52M | $22.94M | $28.40M | 56.18% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
